Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma.

Schalper KA, Rodriguez-Ruiz ME, Diez-Valle R, López-Janeiro A, Porciuncula A, Idoate MA, Inogés S, de Andrea C, López-Diaz de Cerio A, Tejada S, Berraondo P, Villarroel-Espindola F, Choi J, Gúrpide A, Giraldez M, Goicoechea I, Gallego Perez-Larraya J, Sanmamed MF, Perez-Gracia JL, Melero I.

Nat Med. 2019 Feb 11. doi: 10.1038/s41591-018-0339-5. [Epub ahead of print]

PMID:
30742120
2.

A randomized phase II clinical trial of dendritic cell vaccination following complete resection of colon cancer liver metastasis.

Rodriguez J, Castañón E, Perez-Gracia JL, Rodriguez I, Viudez A, Alfaro C, Oñate C, Perez G, Rotellar F, Inogés S, López-Diaz de Cerio A, Resano L, Ponz-Sarvise M, Rodriguez-Ruiz ME, Chopitea A, Vera R, Melero I.

J Immunother Cancer. 2018 Sep 29;6(1):96. doi: 10.1186/s40425-018-0405-z.

3.

Mitochondrial Morphological and Functional Reprogramming Following CD137 (4-1BB) Costimulation.

Teijeira A, Labiano S, Garasa S, Etxeberria I, Santamaría E, Rouzaut A, Enamorado M, Azpilikueta A, Inoges S, Bolaños E, Aznar MA, Sánchez-Paulete AR, Sancho D, Melero I.

Cancer Immunol Res. 2018 Jul;6(7):798-811. doi: 10.1158/2326-6066.CIR-17-0767. Epub 2018 Apr 20.

PMID:
29678874
4.

Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients.

Rodríguez-Ruiz ME, Perez-Gracia JL, Rodríguez I, Alfaro C, Oñate C, Pérez G, Gil-Bazo I, Benito A, Inogés S, López-Diaz de Cerio A, Ponz-Sarvise M, Resano L, Berraondo P, Barbés B, Martin-Algarra S, Gúrpide A, Sanmamed MF, de Andrea C, Salazar AM, Melero I.

Ann Oncol. 2018 May 1;29(5):1312-1319. doi: 10.1093/annonc/mdy089.

PMID:
29554212
5.

Enhancement of antibody-dependent cellular cytotoxicity of cetuximab by a chimeric protein encompassing interleukin-15.

Ochoa MC, Minute L, López A, Pérez-Ruiz E, Gomar C, Vasquez M, Inoges S, Etxeberria I, Rodriguez I, Garasa S, Mayer JA, Wirtz P, Melero I, Berraondo P.

Oncoimmunology. 2017 Nov 13;7(2):e1393597. doi: 10.1080/2162402X.2017.1393597. eCollection 2018.

6.

Identification of LAG3 high affinity aptamers by HT-SELEX and Conserved Motif Accumulation (CMA).

Soldevilla MM, Hervas S, Villanueva H, Lozano T, Rabal O, Oyarzabal J, Lasarte JJ, Bendandi M, Inoges S, López-Díaz de Cerio A, Pastor F.

PLoS One. 2017 Sep 21;12(9):e0185169. doi: 10.1371/journal.pone.0185169. eCollection 2017.

7.

A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients.

Inogés S, Tejada S, de Cerio AL, Gállego Pérez-Larraya J, Espinós J, Idoate MA, Domínguez PD, de Eulate RG, Aristu J, Bendandi M, Pastor F, Alonso M, Andreu E, Cardoso FP, Valle RD.

J Transl Med. 2017 May 12;15(1):104. doi: 10.1186/s12967-017-1202-z.

8.

Antibody-dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells.

Ochoa MC, Minute L, Rodriguez I, Garasa S, Perez-Ruiz E, Inogés S, Melero I, Berraondo P.

Immunol Cell Biol. 2017 Apr;95(4):347-355. doi: 10.1038/icb.2017.6. Epub 2017 Feb 21. Review.

PMID:
28138156
9.

Targeting of PI3K/AKT/mTOR pathway to inhibit T cell activation and prevent graft-versus-host disease development.

Herrero-Sánchez MC, Rodríguez-Serrano C, Almeida J, San Segundo L, Inogés S, Santos-Briz Á, García-Briñón J, Corchete LA, San Miguel JF, Del Cañizo C, Blanco B.

J Hematol Oncol. 2016 Oct 20;9(1):113.

10.

MRP1-CD28 bi-specific oligonucleotide aptamers: target costimulation to drug-resistant melanoma cancer stem cells.

Soldevilla MM, Villanueva H, Casares N, Lasarte JJ, Bendandi M, Inoges S, López-Díaz de Cerio A, Pastor F.

Oncotarget. 2016 Apr 26;7(17):23182-96. doi: 10.18632/oncotarget.8095.

11.

Tumor-Produced Interleukin-8 Attracts Human Myeloid-Derived Suppressor Cells and Elicits Extrusion of Neutrophil Extracellular Traps (NETs).

Alfaro C, Teijeira A, Oñate C, Pérez G, Sanmamed MF, Andueza MP, Alignani D, Labiano S, Azpilikueta A, Rodriguez-Paulete A, Garasa S, Fusco JP, Aznar A, Inogés S, De Pizzol M, Allegretti M, Medina-Echeverz J, Berraondo P, Perez-Gracia JL, Melero I.

Clin Cancer Res. 2016 Aug 1;22(15):3924-36. doi: 10.1158/1078-0432.CCR-15-2463. Epub 2016 Mar 8.

12.

Effect of mTORC1/mTORC2 inhibition on T cell function: potential role in graft-versus-host disease control.

Herrero-Sánchez MC, Rodríguez-Serrano C, Almeida J, San-Segundo L, Inogés S, Santos-Briz Á, García-Briñón J, SanMiguel JF, Del Cañizo C, Blanco B.

Br J Haematol. 2016 Jun;173(5):754-68. doi: 10.1111/bjh.13984. Epub 2016 Feb 23.

PMID:
26914848
13.

Follicular lymphoma: in vitro effects of combining lymphokine-activated killer (LAK) cell-induced cytotoxicity and rituximab- and obinutuzumab-dependent cellular cytotoxicity (ADCC) activity.

García-Muñoz R, López-Díaz-de-Cerio A, Feliu J, Panizo A, Giraldo P, Rodríguez-Calvillo M, Grande C, Pena E, Olave M, Panizo C, Inogés S.

Immunol Res. 2016 Apr;64(2):548-57. doi: 10.1007/s12026-015-8747-9.

PMID:
26659089
14.

2-fluoro-RNA oligonucleotide CD40 targeted aptamers for the control of B lymphoma and bone-marrow aplasia.

Soldevilla MM, Villanueva H, Bendandi M, Inoges S, López-Díaz de Cerio A, Pastor F.

Biomaterials. 2015 Oct;67:274-85. doi: 10.1016/j.biomaterials.2015.07.020. Epub 2015 Jul 14.

PMID:
26231918
15.

Idiotype vaccine production using hybridoma technology.

Inoges S, de Cerio AL, Villanueva H, Pastor F, Bendandi M.

Methods Mol Biol. 2014;1139:367-87. doi: 10.1007/978-1-4939-0345-0_30.

PMID:
24619694
16.

CD28 aptamers as powerful immune response modulators.

Pastor F, Soldevilla MM, Villanueva H, Kolonias D, Inoges S, de Cerio AL, Kandzia R, Klimyuk V, Gleba Y, Gilboa E, Bendandi M.

Mol Ther Nucleic Acids. 2013 Jun 11;2:e98. doi: 10.1038/mtna.2013.26.

17.

Dendritic cell vaccination in glioblastoma after fluorescence-guided resection.

Valle RD, de Cerio AL, Inoges S, Tejada S, Pastor F, Villanueva H, Gallego J, Espinos J, Aristu J, Idoate MA, Andreu E, Bendandi M.

World J Clin Oncol. 2012 Nov 10;3(11):142-9. doi: 10.5306/wjco.v3.i11.142.

18.

Successful idiotypic vaccination following stem cell allotransplant in lymphoma.

de Cerio AL, Inogés S, Ai WZ, Villanueva H, Pastor F, Soldevilla MM, Soria E, Bendandi M.

Leuk Lymphoma. 2013 Apr;54(4):881-4. doi: 10.3109/10428194.2012.721544. Epub 2012 Sep 5. No abstract available.

PMID:
22897725
19.

BiovaxID®: a customized idiotype vaccine for the treatment of B-cell lymphoma.

Villanueva H, de Cerio AL, Inoges S, Pastor F, Soldevilla MM, Bendandi M.

Expert Rev Vaccines. 2011 Dec;10(12):1661-9. doi: 10.1586/erv.11.132.

PMID:
22085168
20.

Idiotype vaccines for lymphoma: Potential factors predicting the induction of immune responses.

Inoges S, de Cerio AL, Villanueva H, Pastor F, Soria E, Bendandi M.

World J Clin Oncol. 2011 Jun 10;2(6):237-44. doi: 10.5306/wjco.v2.i6.237.

21.

Idiotype vaccines for lymphoma therapy.

Inogés S, de Cerio AL, Villanueva H, Soria E, Pastor F, Bendandi M.

Expert Rev Vaccines. 2011 Jun;10(6):801-9. doi: 10.1586/erv.11.44. Review.

PMID:
21692701
22.

Depletion of alloreactive T-cells in vitro using the proteasome inhibitor bortezomib preserves the immune response against pathogens.

Blanco B, Sánchez-Abarca LI, Caballero-Velázquez T, Santamaría C, Inogés S, Pérez-Simón JA.

Leuk Res. 2011 Oct;35(10):1412-5. doi: 10.1016/j.leukres.2011.05.018. Epub 2011 Jun 11.

PMID:
21658766
23.

Stem cell transplant and idiotypic vaccination for B-cell malignancies.

Inoges S, Lopez-Diaz de Cerio A, Sampol A, Nieto J, Soria E, Villanueva H, Pastor F, Bendandi M.

Curr Top Med Chem. 2011;11(13):1653-60. Review.

24.

Rapid, high-yield production in plants of individualized idiotype vaccines for non-Hodgkin's lymphoma.

Bendandi M, Marillonnet S, Kandzia R, Thieme F, Nickstadt A, Herz S, Fröde R, Inogés S, Lòpez-Dìaz de Cerio A, Soria E, Villanueva H, Vancanneyt G, McCormick A, Tusé D, Lenz J, Butler-Ransohoff JE, Klimyuk V, Gleba Y.

Ann Oncol. 2010 Dec;21(12):2420-7. doi: 10.1093/annonc/mdq256. Epub 2010 May 21.

25.

Idiotype vaccines for human B-cell malignancies.

Inoges S, de Cerio AL, Soria E, Villanueva H, Pastor F, Bendandi M.

Curr Pharm Des. 2010 Jan;16(3):300-7. Review.

26.

Prolonged idiotypic vaccination against follicular lymphoma.

Inoges S, Lopez-Diaz de Cerio A, Zabalegui N, Soria E, Villanueva H, Panizo C, Rodriguez-Caballero A, Suarez L, Pastor F, Rodriguez-Calvillo M, Orfao A, Bendandi M.

Leuk Lymphoma. 2009 Jan;50(1):47-53. doi: 10.1080/10428190802601122.

27.

Future of idiotypic vaccination for B-cell lymphoma.

de Cerio AL, Inogés S.

Expert Rev Vaccines. 2009 Jan;8(1):43-50. doi: 10.1586/14760584.8.1.43. Review.

PMID:
19093772
28.

IL-10 suppressor activity and ex vivo Tr1 cell function are impaired in multiple sclerosis.

Martinez-Forero I, Garcia-Munoz R, Martinez-Pasamar S, Inoges S, Lopez-Diaz de Cerio A, Palacios R, Sepulcre J, Moreno B, Gonzalez Z, Fernandez-Diez B, Melero I, Bendandi M, Villoslada P.

Eur J Immunol. 2008 Feb;38(2):576-86. doi: 10.1002/eji.200737271.

29.

[Idiotype vaccines in the treatment of follicular lymphoma: current status and future perspectives].

Zabalegui N, López Díaz de Cerio A, Inogés S, Soria E, Villanueva H, Rivero P.

An Sist Sanit Navar. 2009 Jan-Apr;32(1):61-73. Review. Spanish.

30.

Anti-idiotype antibodies in cancer treatment.

de Cerio AL, Zabalegui N, Rodríguez-Calvillo M, Inogés S, Bendandi M.

Oncogene. 2007 May 28;26(25):3594-602. Review.

31.

Imiquimod enhances the systemic immunity attained by local cryosurgery destruction of melanoma lesions.

Redondo P, del Olmo J, López-Diaz de Cerio A, Inoges S, Marquina M, Melero I, Bendandi M.

J Invest Dermatol. 2007 Jul;127(7):1673-80. Epub 2007 Mar 22.

32.

Human follicular lymphoma cells contain oligomannose glycans in the antigen-binding site of the B-cell receptor.

Radcliffe CM, Arnold JN, Suter DM, Wormald MR, Harvey DJ, Royle L, Mimura Y, Kimura Y, Sim RB, Inogès S, Rodriguez-Calvillo M, Zabalegui N, de Cerio AL, Potter KN, Mockridge CI, Dwek RA, Bendandi M, Rudd PM, Stevenson FK.

J Biol Chem. 2007 Mar 9;282(10):7405-15. Epub 2006 Dec 29.

33.

Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma.

Inogès S, Rodrìguez-Calvillo M, Zabalegui N, Lòpez-Dìaz de Cerio A, Villanueva H, Soria E, Suárez L, Rodríguez-Caballero A, Pastor F, García-Muñóz R, Panizo C, Pèrez-Calvo J, Melero I, Rocha E, Orfao A, Bendandi M; Grupo Español de Linfomas/Trasplante Autologo de Medula Oseo study group; Programa para el Estudio y Tratamiento de Hemopatias Malignas study group.

J Natl Cancer Inst. 2006 Sep 20;98(18):1292-301.

PMID:
16985248
34.

Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation.

Bendandi M, Rodríguez-Calvillo M, Inogés S, López-Díaz de Cerio A, Pérez-Simón JA, Rodríguez-Caballero A, García-Montero A, Almeida J, Zabalegui N, Giraldo P, San Miguel J, Orfao A.

Leuk Lymphoma. 2006 Jan;47(1):29-37.

PMID:
16321824
35.

Expression and serum levels of MMP-2 and MMP-9 during human melanoma progression.

Redondo P, Lloret P, Idoate M, Inoges S.

Clin Exp Dermatol. 2005 Sep;30(5):541-5.

PMID:
16045689
36.

[Past, present and future of anti-idiotype vaccination].

Rodríguez Calvillo M, Inogés S, López Díaz de Cerio A, Zabalegui N, Panizo C, Hernández M, Pérez Calvo J, Prósper F, Melero I, Sánchez-Ibarrola A, Rocha E, Bendandi M.

Rev Med Univ Navarra. 2004 Jul-Sep;48(3):14-23. Review. Spanish.

PMID:
15622921
37.

Imatinib mesylate in cutaneous melanoma.

Redondo P, Lloret P, Andreu EJ, Inoges S.

J Invest Dermatol. 2004 Dec;123(6):1208-9. No abstract available.

38.

Variations in "rescuability" of immunoglobulin molecules from different forms of human lymphoma: implications for anti-idiotype vaccine development.

Rodríguez-Calvillo M, Inogés S, López-Díaz de Cerio A, Zabalegui N, Villanueva H, Bendandi M.

Crit Rev Oncol Hematol. 2004 Oct;52(1):1-7. Review.

PMID:
15363462
39.

[Active immunotherapy in the treatment of haematological neoplasias].

Inogés S, Rodríguez Calvillo M, López Díaz de Cerio A, Zabalegui N, Melero I, Sánchez Ibarrola A, Rocha E, Bendandi M.

An Sist Sanit Navar. 2004 Jan-Apr;27(1):45-62. Review. Spanish.

40.

Acquired potential N-glycosylation sites within the tumor-specific immunoglobulin heavy chains of B-cell malignancies.

Zabalegui N, de Cerio AL, Inogés S, Rodríguez-Calvillo M, Pérez-Calvo J, Hernández M, García-Foncillas J, Martín-Algarra S, Rocha E, Bendandi M.

Haematologica. 2004 May;89(5):541-6.

41.

Imatinib inhibits proliferation of Ewing tumor cells mediated by the stem cell factor/KIT receptor pathway, and sensitizes cells to vincristine and doxorubicin-induced apoptosis.

González I, Andreu EJ, Panizo A, Inogés S, Fontalba A, Fernández-Luna JL, Gaboli M, Sierrasesúmaga L, Martín-Algarra S, Pardo J, Prósper F, de Alava E.

Clin Cancer Res. 2004 Jan 15;10(2):751-61.

42.

Feasibility of idiotype vaccination in relapsed B-cell malignancies.

Inogés S, Rodríguez-Calvillo M, López-Díaz de Cerio A, Zabalegui N, Pérez-Calvo J, Panizo C, Hernandez M, Cuesta B, Rocha E, Bendandi M.

Haematologica. 2003 Dec;88(12):1438-40. No abstract available.

43.

Clinical implications of antigen transfer mechanisms from malignant to dendritic cells. exploiting cross-priming.

Arina A, Tirapu I, Alfaro C, Rodríguez-Calvillo M, Mazzolini G, Inogés S, López A, Feijoo E, Bendandi M, Melero I.

Exp Hematol. 2002 Dec;30(12):1355-64. Review.

44.

Identification of the B-cell tumor-specific molecular fingerprint using non-radiolabelled PCR consensus primers.

Bendandi M, Tonelli R, Maffei R, Botti S, Turi C, Sartini R, Inogés S, Calvillo MR, Zinzani PL, Pession A, Pileri SA, Paolucci G.

Ann Oncol. 2001 Oct;12(10):1479-84.

45.

Factors determining the actual received dose intensity in a program of multicyclic dose-intensive alternating chemotherapy with sequential stem cell support.

Pérez-Calvo J, Martínez-Aguillo M, García-Rayo S, Ramón y Cajal T, Santisteban M, Ordóñez JM, Inogés S, Subirá ML, Martín-Algarra S, Brugarolas A.

Acta Haematol. 2001;105(3):137-42.

PMID:
11463986
46.

Platelet contamination and immunomagnetic cellular selection with the Isolex 300i cell-selection device.

Pérez-Calvo J, Inogés S.

Transfusion. 2000 Oct;40(10):1278-80. No abstract available.

PMID:
11061871
47.

Clinico-pathologic, immunohistochemical, and TUNEL study in early cardiac allograft failure.

Panizo-Santos A, Lozano MD, Distefano S, Inogés S, Pardo J.

Cardiovasc Pathol. 2000 May-Jun;9(3):153-9.

PMID:
10989315
48.

The increase of IFN-gamma production through aging correlates with the expanded CD8(+high)CD28(-)CD57(+) subpopulation.

Bandrés E, Merino J, Vázquez B, Inogés S, Moreno C, Subirá ML, Sánchez-Ibarrola A.

Clin Immunol. 2000 Sep;96(3):230-5.

PMID:
10964541
49.

Cytokine flow cytometry differentiates the clinical status of multiple sclerosis (MS) patients.

Inogés S, Merino J, Bandrés E, De Castro P, Subirá ML, Sánchez-Ibarrola A.

Clin Exp Immunol. 1999 Mar;115(3):521-5.

50.

Progressive decrease of CD8high+ CD28+ CD57- cells with ageing.

Merino J, Martínez-González MA, Rubio M, Inogés S, Sánchez-Ibarrola A, Subirá ML.

Clin Exp Immunol. 1998 Apr;112(1):48-51.

Supplemental Content

Loading ...
Support Center